by admin | Feb 8, 2021 | Press Releases
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE /...
by admin | Nov 17, 2020 | Uncategorized
ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing...
by admin | Nov 17, 2020 | Uncategorized
Monday, June 15, 2020 3:45 PMENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company...
by admin | Nov 17, 2020 | Uncategorized
January 17, 2020 ENB Therapeutics receives IND approval from the FDA for our Phase 1/2 trial evaluating the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. This is a major milestone for ENB and allows our clinical trial to be initiated...
by admin | Feb 4, 2019 | Press Releases
New York, NY., February 4th, 2019 — ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD...
